Endeavor BioMedicines
A USA-based clinical-stage company targeting the drivers of fibrosis and oncology.
Endeavor combines best-in-class therapeutics with an evolving understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Its lead program, ENV-101, is a Hedgehog signalling inhibitor in Phase II studies, as of Q4 2023, treating IPF.
In October 2023, Endeavor acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.
Latest Endeavor BioMedicines News & Features
25 April 2024
14 March 2024
19 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze